CheckMate 017 focused specifically on patients with squamous cell NSCLC. The trial included 272 patients who were randomized to receive either nivolumab or docetaxel. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety.
